Millie Long

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Raymond K. Cross, MD, MS, AGAF, FACG completed undergraduate training at Washington and Jefferson College and attended medical school at the University of Pittsburgh. He completed internal medicine residency and gastroenterology and Hepatology fellowship training at the University of Maryland Medical Center and Baltimore Veterans Affairs. Prior to fellowship, he was a Chief Medical Resident. He obtained a Master’s Degree in Clinical Research at the University of Maryland, Baltimore. He joined the faculty at the University of Maryland and served as Director of the Inflammatory Bowel Disease Program from 2004 to 2024. In July 2024, he joined the faculty at the Melissa L. Posner Institute for Digestive Health & Liver Disease at Mercy Medical Center where he is Director of the Center for Inflammatory Bowel and Colorectal Diseases.
He has published over 200 peer reviewed manuscripts, review articles, and book chapters and has obtained research funding from the Agency for Healthcare Research and Quality, the Crohn’s and Colitis Foundation, and the American College of Gastroenterology. He is past Chair of the Patient Education and Clinical Research Committees and Clinical Research Alliance for the Foundation. He is the Co-Chair of the Regional Advances in Inflammatory Bowel Disease Course, Scientific Co-Director of the CorEvitas Registry, and past Course Director for the American College of Gastroenterology’s Eastern Regional Course. He is Governor for Maryland for the American College of Gastroenterology, a member of the American College of Gastroenterology’s Research Committee, and Senior Associate Editor of the American Journal of Gastroenterology.

Dr. Sara Horst MD, MPH, FACG, AGAF is a Professor in the division of Gastroenterology, Hepatology, & Nutrition at Vanderbilt University Medical Center. Dr. Horst completed her medical school and residency training at The Ohio State University and then went to Vanderbilt University Medical Center for Gastroenterology Fellowship and to obtain her Masters of Public Health. She joined the faculty at Vanderbilt University Medical Center in 2011. She is involved in clinical care of complex IBD care, complex amyloid care, clinical research, and teaching and mentoring medical students and housestaff. She is the medical director for VUMC Specialty Pharmacy, VUMC Telehealth director, and VUMC Associate Vice Chair of Clinical Affairs for Dept of Medicine. Her research interests involve enhancing EHR efficiencies in the care of IBD, telehealth in IBD, and medication adherence in IBD. She has extensively published in peer reviewed journals. She is also involved in clinical care improvement as an EPIC Physician Builder and is on the National EPIC GI Steering Board. She is an associate editor for American Journal of Gastroenterology.

Dr. Hudesman is Director of the Inflammatory Bowel Disease Center at NYU Langone Health. He is Professor of Medicine at the NYU School of Medicine.

Dr. Hudesman specializes in the diagnosis and treatment of inflammatory bowel disease (IBD) and in the provision of integrated, seamless, patient-centered care. His research is focused on the development of biomarkers and evaluation and optimization of new medical therapies for the treatment of both Crohn’s disease and ulcerative colitis.

Dr. Hudesman served on the Educational Affairs Committee of the American College of Gastroenterology, and the Professional Membership Committee of the Crohn’s Colitis Foundation, and is currently on the Quality Committee of the American Gastroenterological Association.

Kelly Issokson, MS, RD, CSDH, LDN, CNSC is the Senior Registered Dietitian of Outpatient Nutrition at the University of California, San Francisco (UCSF) and a nationally recognized expert in gastrointestinal nutrition. With over 17 years of clinical experience, she specializes in inflammatory bowel disease (IBD) and surgical nutrition. Ms. Issokson graduated magna cum laude from Johnson & Wales University and earned her MS in Nutrition from California State University, Northridge. She serves on the National Board of the Crohn’s & Colitis Foundation and is a leading voice in advancing nutrition as part of multidisciplinary IBD care. She co-developed the Cedars-Sinai IBD Prehabilitation Program and nutrition education training programs for physicians, APPs, and RDs.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Jessiy Salwen-Deremer, Ph.D., DBSM, is the Director of Behavioral Medicine for Digestive Health at Dartmouth-Hitchcock Medical Center and Assistant Professor of Psychiatry & Medicine at the Geisel School of Medicine at Dartmouth. Dr. Salwen-Deremer earned her Ph.D. in clinical psychology at Stony Brook University and completed her fellowship training in behavioral medicine at the Johns Hopkins School of Medicine. Her areas of clinical expertise include behavioral sleep medicine and gastropsychology. Her research expertise encompasses two areas: understanding the impact of sleep disorders on inflammatory bowel diseases and improving access to gastrointestinal behavioral health care. Across both of these areas, she focuses on the integration of telehealth and remote technologies to enhance patient engagement and participation.

Marla C. Dubinsky received a medical degree from Queen’s University in Canada and completed her clinical pediatric gastroenterology training at Sainte-Justine Hospital, University of Montreal in Quebec, Canada adn her IBD training at Cedars-SInai Medical Center, Los Angeles, CA. Dr. Dubinsky is a proud recipient of the 2022 Sherman Prize for Excellence in Crohn’s and Colitis and a 2024 Jacobi Medallion winner for her contibutions to Mount Sinai. Currently, Dr. Dubinsky is Chief of Pediatric Gastroenterology and Nutrition, as well as the Co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center and Co-director of the Marie and Barry Lipman Preconception and Pregnancy Planning Clinic at Mount Sinai Hospital, New York, She is a Professor of both Pediatrics and Medicine at the Icahn School of Medicine, Her primary research focuses on the influence of genetics and immune responses on the variability in clinical presentations, treatment responses and prognosis of IBD. Her other interests include the impact of IBD on fertility and pregnancy. She has lectured widely both nationally and internationally and has published in over 400 peer reviewed journals including New England Journal of Medicine, Lancet, Gastroenterology, The American Journal of Gastroenterology, The Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, and of Crohn's and Colitis .

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Dr. Aline Charabaty is Professor of Medicine at the University of Maryland and the Director of the IBD Program at the University of Maryland Medical center. She is the Editor-in-Chief of the Crohn’s and Colitis 360 journal, and is past Vice-Chair of the AGA Research Foundation Executive Board, and past ACG Governor for Washington DC. Her work and advocacy were recognized by the Crohn’s and Colitis Foundation Excellence in Medicine Award in 2020 , the ACG Diversity Equity and Inclusion Award in 2025, and the AGA Beacon of Hope Award in 2026. Dr Charabaty uses social media to amplify medical education in IBD and is the founder of @MondayNightIBD a CME platform on twitter for which she received the Healio Disruptive Innovator Award in 2019. Dr Charabaty is a strong advocate for diversity and the professional advancement of women in GI. She is the Co-Founder of Scrubs & Heels, a foundation focused on empowering women in GI with the leadership skills, networking and mentorship to achieve professional goals and growth.

Dr. Kara De Felice serves as an Associate Professor of Clinical Medicine and the Director of Inflammatory Bowel Diseases at the University of Cincinnati. Leading a multidisciplinary IBD team, her mission is to deliver exceptional patient care and improve long-term outcomes through clinical excellence, participation in clinical trials, and the training of the next generation of gastroenterologists. A dedicated educator, she is a frequent speaker at regional and national conferences with a specialized focus on women in GI and Advanced Practice Provider (APP) education. Outside of the clinic, she enjoys traveling, playing tennis, and hosting dinner and cocktail parties.

Dr. Christina Ha completed her internal medicine residency and fellowship at the Washington University in St. Louis School of Medicine and then received additional training as the Present-Levison Inflammatory Bowel Diseases Fellow at the Mount Sinai School of Medicine. She is Director of the Inflammatory Bowel Disease Section and Associate Professor of Medicine at Mayo Clinic Arizona. Her clinical research interests focus on the impact of aging on the natural history of the inflammatory bowel diseases, especially the pathogenesis and natural history of late-onset IBD. She is also very involved in IBD related trainee educational initiatives and has served on multiple committees within the Crohn’s and Colitis Foundation, American College of Gastroenterology, and American Gastroenterological Association.

Dr. Maia Kayal is an Associate Professor in the Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai and The Susan and Leonard Feinstein IBD Center. She graduated from New York University School of Medicine Alpha Omega Alpha. She then completed her internal medicine residency at Columbia University Medical Center-New York Presbyterian Hospital and fellowship training in gastroenterology at the Mount Sinai Hospital. Dr. Kayal's research in inflammatory conditions of the ileal pouch is funded by the NIH, Crohn’s and Colitis Foundation, and Rainin Foundation. She is a former ACG Young Physicians Leadership Scholar and AGA Future Leader.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Dr. Miguel Regueiro is the Enterprise Chief of Staff and Executive Vice President at Cleveland Clinic, and Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Regueiro is the inaugural Chair holder of The Melody and Steve Golding Chair for Digestive Diseases. He served as the Global Chief for the Digestive Disease Institute from 2021 - 2026 before becoming Enterprise Chief of Staff. As Chief of Staff, he is responsible for shaping the healthcare strategy and vision for the national and international Cleveland Clinic sites. He oversees 6,000 physicians and 4.000 advanced practice providers across the enterprise.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course and medical-surgical management of Crohn’s disease and ulcerative colitis. He leads research on postoperative prevention of Crohn’s disease, as well as developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.

Corey A. Siegel, MD, MS, is the Director of the Walter and Carole Young Center for Digestive Health at the Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire. He is the Constantine and Joyce Hampers Professor of Medicine and a Professor at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.

Dr. Siegel received his medical degree from Tufts University School of Medicine in Boston, Massachusetts. He completed his residency in internal medicine at the Dartmouth Hitchcock Medical Center where he also served as chief medical resident. He then completed a fellowship in Gastroenterology at Dartmouth Hitchcock followed by a fellowship in Inflammatory Bowel Disease at Massachusetts General Hospital in Boston.

Dr. Siegel’s research interests include understanding risk/benefit tradeoffs in IBD, developing models to predict outcomes in Crohn’s disease, creating tools to facilitate shared decision making, expanding telemedicine services to patients with IBD living in rural locations, and improving the quality of care delivered to patients with IBD. He has been funded by the NIH, AHRQ, the Crohn’s and Colitis Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust for this work. Dr. Siegel is the founder of the BRIDGe group, an international research collaborative of IBD investigators. Dr. Siegel was inducted into the International Organization for the Study of IBD (IOIBD) in 2013 and he received the Sherman Prize in 2023. He lives in Hanover, New Hampshire with his wife and three boys.

Dr. Hanauer is the Clifford Joseph Barborka Professor of Medicine and Medical Director of the Digestive Health Center at Northwestern University’s Feinberg School of Medicine since 2014. Dr. Hanauer received his medical degree from the University of Illinois Chicago, and he completed his residency in internal medicine and a fellowship in gastroenterology at the University of Chicago in 1982. In 2014, Dr. Hanauer was named the Medical Director of the Digestive Health Center at Northwestern Medicine and the Clifford Joseph Barborka Professor of Medicine in the Northwestern University’s Feinberg School of Medicine, where he continues to treat IBD patients and conducts research into new therapies.

Dr. Hanauer is a Fellow and past President of the American College of Gastroenterology (ACG) and the former Chair of the American Gastroenterological Association’s Inflammation, Immunology, and IBD Section. In October 2020, received the Master of the American College of Gastroenterology.

Internationally recognized expert on the treatment of inflammatory bowel disease (IBD), former chair of the FDA Gastrointestinal Drugs Advisory Committee and advisor on the development of multiple leading IBD drugs. Dr. Hanauer has expertise in designing and leading clinical studies for IBD related therapies and has acted as a clinical investigator and/or advisor to pharmaceutical companies in the development of most of the leading IBD therapies.

Dr. Hanauer has authored over 500 peer-reviewed journal articles and numerous books and book chapters, abstracts, monographs, and editorials. He has been a reviewer for NEJM, Annals of Internal Medicine, Lancet, Gastroenterology and numerous specialty journals.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Dr. Jessica Allegretti currently serves as the Medical Director of the Crohn’s and Colitis Center at the Brigham and Women’s Hospital. In 2020, she received the Sherman Emerging Leader Prize for Excellence in Crohn’s and Colitis. In addition, she developed and leads the hospital’s Fecal Microbiota Transplantation Program and has grown to become and international expert on the topic. Dr. Allegretti cares for patients with inflammatory bowel disease as well as Clostridioides difficile (c.diff) infection. Her research focuses on the intestinal microbiome and the consequences of its derangement, with the goal of understanding the role dysbiosis plays in microbial associated diseases. In addition, her lab focuses on novel therapeutic agents for IBD and she is leading multiple sponsored and investigator initiated drug trials. For more information visit www.allegrettilab.com

Marla C. Dubinsky received a medical degree from Queen’s University in Canada and completed her clinical pediatric gastroenterology training at Sainte-Justine Hospital, University of Montreal in Quebec, Canada adn her IBD training at Cedars-SInai Medical Center, Los Angeles, CA. Dr. Dubinsky is a proud recipient of the 2022 Sherman Prize for Excellence in Crohn’s and Colitis and a 2024 Jacobi Medallion winner for her contibutions to Mount Sinai. Currently, Dr. Dubinsky is Chief of Pediatric Gastroenterology and Nutrition, as well as the Co-Director of the Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center and Co-director of the Marie and Barry Lipman Preconception and Pregnancy Planning Clinic at Mount Sinai Hospital, New York, She is a Professor of both Pediatrics and Medicine at the Icahn School of Medicine, Her primary research focuses on the influence of genetics and immune responses on the variability in clinical presentations, treatment responses and prognosis of IBD. Her other interests include the impact of IBD on fertility and pregnancy. She has lectured widely both nationally and internationally and has published in over 400 peer reviewed journals including New England Journal of Medicine, Lancet, Gastroenterology, The American Journal of Gastroenterology, The Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, and of Crohn's and Colitis .

Professor Remo Panaccione is a Professor of Medicine and the Director of the Inflammatory Bowel Disease Unit at the University of Calgary, Canada. He serves as the Dean of MD Admissions and Director of the IBD Fellowship Program. He also holds the Crohn’s Colitis Canada Endowed Research Chair in Inflammatory Bowel Disease.

He is the 2020 Crohn's Colitis Canada Outstanding Physician of the Year and received the 2024 Crohn’s Colitis Canada Research Leadership Award for his contributions to the field. Since 2020 he has been a Clarivate Research Scholar for being cited in the top one percent of researchers in the world. He has co-authored over 500 manuscripts, 20 book chapters and 825 abstracts, including publications in journals such as the New England Journal of Medicine, The Lancet, JAMA, Nature, and Annals of Internal Medicine.

Prof. Panaccione’s main research interest is the design and implementation of clinical trials. He has been the principal investigator on several studies evaluating the efficacy and safety of new therapeutic agents in subjects with IBD.

Dr. Rieder is Vice Chair and Co-Director of the IBD section at the Department of Gastroenterology, Hepatology and Nutrition at the Cleveland Clinic, Cleveland. His clinical focus is patients with IBD with a special emphasis on the field of pathogenesis, prediction and therapy of intestinal fibrosis. Dr. Rieder has published more than 200 articles and book chapters and has been recognized for his expertise as indicated through invitations to clinical guideline steering committees of the European Crohn’s and Colitis Organization (ECCO). He is lead author of the ECCO guidelines on Ulcerative colitis and lead author of the first ECCO clinical consensus on ‘Diagnosis and Management of Intestinal Fibrosis’. He received multiple international invitations as a speaker, session chair or conference faculty. Dr. Rieder serves as an abstract reviewer for all major GI conferences, he is past associate editor (Clinical and Translational Gastroenterology) and on several editorial boards of medical journals. He is proud of his significant ties to the ECCO, which he served as the chair of Y-ECCO, member of the ECCO operational board, prior Y-ECCO committee member and member of the scientific committee. He is past chair of REACH-IBD and Co-Chair of the Professional Education Committee of the Crohn’s and Colitis Foundation. Dr. Rieder is the leading PI on the international Stenosis Therapy and Research (STAR) Consortium with the goal to build a pathway to test anti-fibrotic medications in stricturing Crohn’s disease. He received the Sherman Emerging Leader Prize in 2019.

David T. Rubin is the Joseph B. Kirsner Professor of Medicine, Professor of Pathology, Chief of the Section of Gastroenterology, Hepatology & Nutrition and Director of the Inflammatory Bowel Disease Center at the University of Chicago Medicine. He earned a medical degree with honors at The University of Chicago Pritzker School of Medicine where he also completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics. He is associate faculty member at the MacLean Center for Clinical Medical Ethics, associate investigator at the University of Chicago Comprehensive Cancer Center and a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the immediate past Chair of the National Scientific Advisory Committee of the Crohn’s & Colitis Foundation and Deputy Chair of the International Organization for the Study of IBD.
Dr. Rubin’s research is focused on disease modification in IBD including clinical trial designs, novel measures of inflammation and prevention of adverse outcomes, and quality of life in IBD. In 2023, he received both the UChicago Michael Reese Lectureship Award (for outstanding faculty who have developed novel teaching and clinical research that advances healthcare) and the distinguished UChicago Arthur H. Rubenstein Mentorship in Academic Medicine Award. Dr. Rubin is currently a senior editor of the 12 edition of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, and an author on >600 articles on management of IBD, including the 2019 and 2025 ACG Guidelines for ulcerative colitis.

Dr. Cheifetz is Director of the Center for Inflammatory Bowel Disease and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology Clerkship Elective and Associate Director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center.
Dr. Cheifetz specializes in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published over 250 articles and chapters on the subject. His research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care. Dr. Cheifetz lectures nationally and internationally on IBD. Dr. Cheifetz is also actively involved in teaching and mentoring medical students, residents, and fellows, and is proud to have trained numerous physicians who now specialize in IBD and direct their own centers.

Dr. Bridget E. Shields is the Susan Nicholas Fasciano Family Foundation Professor of Inflammatory Skin Diseases, Associate Professor, and Director of the Clinical and Translational Research Program in the Department of Dermatology at the University of Wisconsin–Madison. She completed her dermatology residency at the University of Wisconsin, where she served as Chief Resident, followed by a fellowship in Complex Medical Dermatology at the University of Pennsylvania with specialized training in granulomatous skin diseases, including cutaneous Crohn disesae. Dr. Shields directs the University of Wisconsin's specialized IBD-Dermatology clinic and serves on the inpatient dermatology consultation service, caring for patients with complex inflammatory skin disorders. She also leads the University of Wisconsin Multidisciplinary Sarcoidosis Program, fostering collaboration among clinicians and scientists to improve the understanding and treatment of systemic granulomatous disease.
As a clinician-scientist, Dr. Shields' research focuses on defining the molecular mechanisms underlying skin manifestations of IBD through spatial transcriptomics, multiomics, and translational immunology, with the goal of developing precision diagnostics and targeted therapies.
Dr. Shields has authored more than 70 peer-reviewed scientific publications and numerous invited book chapters. She is a nationally recognized speaker who has delivered invited lectures on skin manifestations of IBD and other inflammatory dermatologic disorders at regional and national scientific meetings.
Her research program has been supported by the Dermatology Foundation Medical Dermatology Career Development Award and the Ann Theodore Foundation, among other competitive funding sources.

Oriana M. Damas, MD, MSCTI, is an Associate Professor of Medicine at the University of Miami Miller School of Medicine. She also serves as the Director of Translational Studies for the Crohn’s and Colitis Center. Dr. Damas earned her medical degree from the University of Miami and completed her training in internal medicine and gastroenterology at the University of Miami and Jackson Memorial Hospital.

Her clinical practice and research focus on the care of patients with inflammatory bowel disease (IBD). Dr. Damas has conducted extensive research on environmental factors and the epidemiology of IBD. Her contributions to the field have earned her accolades, including the DREAM Award in recognition of her work with the Hispanic IBD community.

Dr. Damas has significant experience in running clinical trials, including innovative dietary trials, aimed at improving the quality of life for patients with IBD through lifestyle and dietary modifications. She is an NIH-funded researcher and currently serves as the principal investigator for a study developing an anti-inflammatory South Florida diet for IBD patients, which incorporates elements of traditional Latin foods from the region.

She has authored numerous original research articles, and she serves on the Editorial Boards of the prestigious Gastroenterology journal and Crohn’s & Colitis 360. In addition to her research, Dr. Damas is recognized as a national and international leader in her field. She is frequently invited to speak at national and international conferences and is an active member of the AGA n and the Crohn’s & Colitis Foundation.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Jason Schairer is the Director of the Henry Ford IBD Center in Michigan. His interests include Interventional IBD with a focus on stricturotomy, addressing health care inequity, intimacy and sex in IBD, and improving medical education for providers of all levels. He received his medical degree from Wayne Statue University, and went on to complete a fellowship in gastroenterology at Providence Hospital in Michigan. He previously served as the Associate Program Director of the Henry Ford Gastroenterology and Hepatology fellowship, and continues to be involved in fellow education of IBD across the state of Michigan. He has been recognized for his teaching efforts, high quality care of IBD patients and contributions to patient education. He has presented at ESCCO, AIBD and DDW. He is Vice President of the Interventional IBD Special Interest Group of ASGE. He is President of the Oakland County Medical Society. He is also active on social media including Twitter and Youtube.

Dr. Cheifetz is Director of the Center for Inflammatory Bowel Disease and Medical Director of Infusion Services at Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. He is also Director of the Harvard Medical School Gastroenterology Clerkship Elective and Associate Director of the Advanced Fellowship in Inflammatory Bowel Disease at Beth Israel Deaconess Medical Center.
Dr. Cheifetz specializes in the treatment of Crohn’s disease, ulcerative colitis, and other inflammatory bowel diseases. In addition to his clinical work, he is involved in multiple research projects relating to IBD and has published over 250 articles and chapters on the subject. His research currently focuses on optimizing the use of biologics through the proactive use of drug concentrations and antibodies, and he has published extensively in this area. Dr. Cheifetz was the first to demonstrate that proactive monitoring of infliximab and adalimumab concentrations and dosing to a therapeutic window improves outcomes when compared to standard of care. Dr. Cheifetz lectures nationally and internationally on IBD. Dr. Cheifetz is also actively involved in teaching and mentoring medical students, residents, and fellows, and is proud to have trained numerous physicians who now specialize in IBD and direct their own centers.

Dr. Bridget E. Shields is the Susan Nicholas Fasciano Family Foundation Professor of Inflammatory Skin Diseases, Associate Professor, and Director of the Clinical and Translational Research Program in the Department of Dermatology at the University of Wisconsin–Madison. She completed her dermatology residency at the University of Wisconsin, where she served as Chief Resident, followed by a fellowship in Complex Medical Dermatology at the University of Pennsylvania with specialized training in granulomatous skin diseases, including cutaneous Crohn disesae. Dr. Shields directs the University of Wisconsin's specialized IBD-Dermatology clinic and serves on the inpatient dermatology consultation service, caring for patients with complex inflammatory skin disorders. She also leads the University of Wisconsin Multidisciplinary Sarcoidosis Program, fostering collaboration among clinicians and scientists to improve the understanding and treatment of systemic granulomatous disease.
As a clinician-scientist, Dr. Shields' research focuses on defining the molecular mechanisms underlying skin manifestations of IBD through spatial transcriptomics, multiomics, and translational immunology, with the goal of developing precision diagnostics and targeted therapies.
Dr. Shields has authored more than 70 peer-reviewed scientific publications and numerous invited book chapters. She is a nationally recognized speaker who has delivered invited lectures on skin manifestations of IBD and other inflammatory dermatologic disorders at regional and national scientific meetings.
Her research program has been supported by the Dermatology Foundation Medical Dermatology Career Development Award and the Ann Theodore Foundation, among other competitive funding sources.

Oriana M. Damas, MD, MSCTI, is an Associate Professor of Medicine at the University of Miami Miller School of Medicine. She also serves as the Director of Translational Studies for the Crohn’s and Colitis Center. Dr. Damas earned her medical degree from the University of Miami and completed her training in internal medicine and gastroenterology at the University of Miami and Jackson Memorial Hospital.

Her clinical practice and research focus on the care of patients with inflammatory bowel disease (IBD). Dr. Damas has conducted extensive research on environmental factors and the epidemiology of IBD. Her contributions to the field have earned her accolades, including the DREAM Award in recognition of her work with the Hispanic IBD community.

Dr. Damas has significant experience in running clinical trials, including innovative dietary trials, aimed at improving the quality of life for patients with IBD through lifestyle and dietary modifications. She is an NIH-funded researcher and currently serves as the principal investigator for a study developing an anti-inflammatory South Florida diet for IBD patients, which incorporates elements of traditional Latin foods from the region.

She has authored numerous original research articles, and she serves on the Editorial Boards of the prestigious Gastroenterology journal and Crohn’s & Colitis 360. In addition to her research, Dr. Damas is recognized as a national and international leader in her field. She is frequently invited to speak at national and international conferences and is an active member of the AGA n and the Crohn’s & Colitis Foundation.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Jason Schairer is the Director of the Henry Ford IBD Center in Michigan. His interests include Interventional IBD with a focus on stricturotomy, addressing health care inequity, intimacy and sex in IBD, and improving medical education for providers of all levels. He received his medical degree from Wayne Statue University, and went on to complete a fellowship in gastroenterology at Providence Hospital in Michigan. He previously served as the Associate Program Director of the Henry Ford Gastroenterology and Hepatology fellowship, and continues to be involved in fellow education of IBD across the state of Michigan. He has been recognized for his teaching efforts, high quality care of IBD patients and contributions to patient education. He has presented at ESCCO, AIBD and DDW. He is Vice President of the Interventional IBD Special Interest Group of ASGE. He is President of the Oakland County Medical Society. He is also active on social media including Twitter and Youtube.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Corey A. Siegel, MD, MS, is the Director of the Walter and Carole Young Center for Digestive Health at the Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire. He is the Constantine and Joyce Hampers Professor of Medicine and a Professor at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.

Dr. Siegel received his medical degree from Tufts University School of Medicine in Boston, Massachusetts. He completed his residency in internal medicine at the Dartmouth Hitchcock Medical Center where he also served as chief medical resident. He then completed a fellowship in Gastroenterology at Dartmouth Hitchcock followed by a fellowship in Inflammatory Bowel Disease at Massachusetts General Hospital in Boston.

Dr. Siegel’s research interests include understanding risk/benefit tradeoffs in IBD, developing models to predict outcomes in Crohn’s disease, creating tools to facilitate shared decision making, expanding telemedicine services to patients with IBD living in rural locations, and improving the quality of care delivered to patients with IBD. He has been funded by the NIH, AHRQ, the Crohn’s and Colitis Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust for this work. Dr. Siegel is the founder of the BRIDGe group, an international research collaborative of IBD investigators. Dr. Siegel was inducted into the International Organization for the Study of IBD (IOIBD) in 2013 and he received the Sherman Prize in 2023. He lives in Hanover, New Hampshire with his wife and three boys.

Dr Nayantara Coelho-Prabhu is Professor of Medicine at the Mayo Clinic in Rochester MN. She also currently serves as the ACG Governor for MN. Her research and clinical interests are in the detection and management of dysplasia in inflammatory bowel disease including advanced endoscopic imaging and resection techniques. She has extensive experience in management of gastrointestinal bleeding and advanced endoscopic therapies in the management of complications of IBD. She has published extensively in this field and mentored mutliple trainees. She also co-leads the artificial intelligence in endoscopy program at the Mayo Clinic Rochester, and is actively involved in the development and validation of endoscopy AI algorithms. The team she leads has developed a first-of its-kind digital endoscopy platform upon which further internal and external projects will exist. One of these already developed is a CADe for dysplastic lesions in IBD. She has spoken at multiple national and international meetings on these topics.

Dr. Grossman is the Associate Clinic Chief of Gastroenterology, Hepatology, and Nutrition and Co-Director of the Center for Pediatric Inflammatory Bowel Disease at the Children’s Hospital of Philadelphia and the Robert N. Baldassano MD Professor of Clinical Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. Dr. Grossman has dedicated his career to advancing the quality of clinical care and promoting a multidisciplinary approach for children and adolescents with IBD. He has led national committees for the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and ImproveCareNow (ICN). He has been involved with the Crohn’s & Colitis Foundation for years, serving on the Board of Directors and the Chapter Medical Advisory Committee for the Philadelphia/Delaware Valley chapter, as well as serving as chair of the Pediatric Affairs Committee on the National Scientific Advisory Committee (NSAC). He has co-authored multiple research publications, is an editor of the Pediatric Inflammatory Bowel Disease textbook, and frequently lectures at national scientific meetings.

Dr. Hanauer is the Clifford Joseph Barborka Professor of Medicine and Medical Director of the Digestive Health Center at Northwestern University’s Feinberg School of Medicine since 2014. Dr. Hanauer received his medical degree from the University of Illinois Chicago, and he completed his residency in internal medicine and a fellowship in gastroenterology at the University of Chicago in 1982. In 2014, Dr. Hanauer was named the Medical Director of the Digestive Health Center at Northwestern Medicine and the Clifford Joseph Barborka Professor of Medicine in the Northwestern University’s Feinberg School of Medicine, where he continues to treat IBD patients and conducts research into new therapies.

Dr. Hanauer is a Fellow and past President of the American College of Gastroenterology (ACG) and the former Chair of the American Gastroenterological Association’s Inflammation, Immunology, and IBD Section. In October 2020, received the Master of the American College of Gastroenterology.

Internationally recognized expert on the treatment of inflammatory bowel disease (IBD), former chair of the FDA Gastrointestinal Drugs Advisory Committee and advisor on the development of multiple leading IBD drugs. Dr. Hanauer has expertise in designing and leading clinical studies for IBD related therapies and has acted as a clinical investigator and/or advisor to pharmaceutical companies in the development of most of the leading IBD therapies.

Dr. Hanauer has authored over 500 peer-reviewed journal articles and numerous books and book chapters, abstracts, monographs, and editorials. He has been a reviewer for NEJM, Annals of Internal Medicine, Lancet, Gastroenterology and numerous specialty journals.

Paulo Gustavo Kotze is Adjunct Senior Professor of Surgery at the Catholic University in Curitiba, Paraná, Brazil. He rcompleted his General Surgery training at the Evangelical University Hospital in Curitiba (2000). He also completed his senior Fellowship in Colorectal Surgery at the Clinics Hospital from the Federal University of Parana (2002). Dr. Kotze achieved his Masters' Degree on Surgery at the Catholic University in 2008 and joined the faculty of medicine at the same university in 2011. He achieved his PhD degree studying the influence of biological therapy on surgical outcomes in Crohn´s disease, in the University of Campinas, in São Paulo, Brazil (UNICAMP) in 2015. Dr. Kotze was also an IBD advanced visiting fellow in the IBD unit at the University of Calgary (Cumming school of medicine), Canada, for the period of 2017-2018. Dr. Kotze is an experienced IBD surgeon and author of 3 books, 250+ pubmed peer-reviewed articles and multiple book chapters focused on Crohn´s disease and ulcerative colitis. He has special interest in the fields of biological therapy, epidemiology and surgery in IBD. Dr. Kotze was formely a committee member of S-ECCO (surgeons of ECCO) from 2015-2018 and a member of the ECCO EduCOM (educational committee), 2018-2021. He is an active member from the International Organization of Inflammatory Bowel Diseases (IOIBD). Currently, he is Professor of the Health Sciences Postgraduate Program at the Catholic University of Paraná, in Curitiba, Brazil. Dr Kotze is also a senior researcher for the National Brazilian Council of Research (CNPq).

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Dr. Miguel Regueiro is the Enterprise Chief of Staff and Executive Vice President at Cleveland Clinic, and Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Regueiro is the inaugural Chair holder of The Melody and Steve Golding Chair for Digestive Diseases. He served as the Global Chief for the Digestive Disease Institute from 2021 - 2026 before becoming Enterprise Chief of Staff. As Chief of Staff, he is responsible for shaping the healthcare strategy and vision for the national and international Cleveland Clinic sites. He oversees 6,000 physicians and 4.000 advanced practice providers across the enterprise.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course and medical-surgical management of Crohn’s disease and ulcerative colitis. He leads research on postoperative prevention of Crohn’s disease, as well as developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.

Corey A. Siegel, MD, MS, is the Director of the Walter and Carole Young Center for Digestive Health at the Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire. He is the Constantine and Joyce Hampers Professor of Medicine and a Professor at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.

Dr. Siegel received his medical degree from Tufts University School of Medicine in Boston, Massachusetts. He completed his residency in internal medicine at the Dartmouth Hitchcock Medical Center where he also served as chief medical resident. He then completed a fellowship in Gastroenterology at Dartmouth Hitchcock followed by a fellowship in Inflammatory Bowel Disease at Massachusetts General Hospital in Boston.

Dr. Siegel’s research interests include understanding risk/benefit tradeoffs in IBD, developing models to predict outcomes in Crohn’s disease, creating tools to facilitate shared decision making, expanding telemedicine services to patients with IBD living in rural locations, and improving the quality of care delivered to patients with IBD. He has been funded by the NIH, AHRQ, the Crohn’s and Colitis Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust for this work. Dr. Siegel is the founder of the BRIDGe group, an international research collaborative of IBD investigators. Dr. Siegel was inducted into the International Organization for the Study of IBD (IOIBD) in 2013 and he received the Sherman Prize in 2023. He lives in Hanover, New Hampshire with his wife and three boys.

James Lewis, MD, MSCE, is Professor of Medicine and Epidemiology, Senior Scholar in the Center for Clinical Epidemiology and Biostatistics, LDI Senior Fellow, Vice-Chief for Research (Clinical) in the Division of Gastroenterology and Hepatology at the University of Pennsylvania’s Perelman School of Medicine and Chief of Gastroenterology at Penn Presbyterian Medical Center in Philadelphia, Pennsylvania. Dr. Lewis is a gastroenterologist with a focus on caring for patients with inflammatory bowel diseases (IBD) and has conducted clinical research related to IBD for nearly 30 years. His reserach includes epidemiology studies focusing on optimal choice of therapies and treatment patterns and investigator-initiated multicenter clinical trials of medications and behavioral interventions, particulalry related to dietary patterns. His work has been funded by the NIH, AHRQ, CDC, PCORI, and numerous foundations and corporate sponsors. Dr. Lewis is the lead scientist for the Crohn's & Colitis Foundation’s IBD Plexus Research Program. He is an elected member of the American Society for Clinical Investigation and the Association of American Physicians. In 2016, he received the Sherman Prize for Excellence in Crohn’s and Colitis.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Dr. Kaplan is a Professor in the Cumming School of Medicine at the University of Calgary. Dr. Kaplan is a gastroenterologist who is internationally renowned for studying the global epidemiology of inflammatory bowel disease (IBD). As the corresponding author, he has published in prestigious journals such as Nature, The Lancet and JAMA. He is an Associate Editor of Gastroenterology and an Academic Editor of PLOS Med. Between 2020 and 2025 Clarivate, Web of Science named Dr. Kaplan a Highly Cited Researcher in recognition of being in the top one percent of cited researchers. Dr. Kaplan is a member of the International Organization for the study of IBD (IOIBD). Dr. Kaplan received Canadian Association of Gastroenterology’s Research Leader Award and was inducted into the Canadian Academy of Health Sciences.

Dr Nuru Noor is a Clinical Lecturer in Gastroenterology based at the University of Cambridge in the UK. He also works as a Postdoctoral Research Associate at the Medical Research Council Clinical Trials Unit - the largest academic clinical trials unit in Europe. He has a particular interest in novel clinical trial designs, having completed his PhD on this topic. He is keen to bring novel methodological approaches to the field of Gastroenterology, and in particular to IBD - which is his main area of clinical interest and expertise.

Bruce Sands, MD, MS is the Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. Dr. Sands is an expert in the management of IBD and has earned an international reputation for his care of patients with complex and refractory disease. Dr. Sands was awarded his BA and MD from Boston University, and trained in internal medicine at the Hospital of the University of Pennsylvania. After completing GI fellowship at the Massachusetts General Hospital, he joined the faculty of Harvard Medical School and served as the Acting Chief of the Gastrointestinal Unit at MGH before moving to Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Dr. Sands is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics. Dr. Sands' research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD in Rhode Island. Dr. Sands is a past chair of the Clinical Research Alliance of the Crohn's & Colitis Foundation of America and served as Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association. Additionally, Dr. Sands was the Chair of the International Organization for the Study of IBD (IOIBD). In 2016 Dr. Sands was awarded the Dr. Henry Janowitz Lifetime Achievement Award from the Crohn’s & Colitis Foundation of America, that organization’s highest honor.

Prateek Sharma, MD, MASGE is currently Professor of Medicine at the University of Kansas School of Medicine. He completed his internal medicine residency at the Medical College of Wisconsin in Milwaukee and his gastroenterology fellowship at the University of Arizona in Tucson. Dr. Sharma has been at the forefront in improving diagnosis and management of GI diseases and cancer, specifically in advanced imaging and endoscopic treatments. He is a world-renowned physician, teacher, and educator who has been interviewed by the Wall Street Journal and Newsweek.

Dr. Sharma's research has focused on upper gastrointestinal diseases including Barrett's esophagus, esophageal cancer, and gastroesophageal reflux disease. He received the ACG Governors Award for Excellence in Clinical Research. He has over 400 publications, including original articles and book chapters, and is regularly invited to present at major national and international meetings. In addition, he has co-edited several important books. Dr. Sharma has and continues to publish in several high-profile national and international journals, including the New England Journal of Medicine, Annals of Internal Medicine, Gastrointestinal Endoscopy, Gastroenterology, and American Journal of Gastroenterology. Dr. Sharma is currently a Governing Board Member and Treasurer of the American Society for Gastrointestinal Endoscopy.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Dr. Miguel Regueiro is the Enterprise Chief of Staff and Executive Vice President at Cleveland Clinic, and Professor in the Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Dr. Regueiro is the inaugural Chair holder of The Melody and Steve Golding Chair for Digestive Diseases. He served as the Global Chief for the Digestive Disease Institute from 2021 - 2026 before becoming Enterprise Chief of Staff. As Chief of Staff, he is responsible for shaping the healthcare strategy and vision for the national and international Cleveland Clinic sites. He oversees 6,000 physicians and 4.000 advanced practice providers across the enterprise.

Dr. Regueiro’s main clinical and research interest is Inflammatory Bowel Diseases (IBD) with a focus on the natural course and medical-surgical management of Crohn’s disease and ulcerative colitis. He leads research on postoperative prevention of Crohn’s disease, as well as developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.

Corey A. Siegel, MD, MS, is the Director of the Walter and Carole Young Center for Digestive Health at the Dartmouth Hitchcock Medical Center in Lebanon, New Hampshire. He is the Constantine and Joyce Hampers Professor of Medicine and a Professor at The Dartmouth Institute for Health Policy and Clinical Practice at the Geisel School of Medicine at Dartmouth.

Dr. Siegel received his medical degree from Tufts University School of Medicine in Boston, Massachusetts. He completed his residency in internal medicine at the Dartmouth Hitchcock Medical Center where he also served as chief medical resident. He then completed a fellowship in Gastroenterology at Dartmouth Hitchcock followed by a fellowship in Inflammatory Bowel Disease at Massachusetts General Hospital in Boston.

Dr. Siegel’s research interests include understanding risk/benefit tradeoffs in IBD, developing models to predict outcomes in Crohn’s disease, creating tools to facilitate shared decision making, expanding telemedicine services to patients with IBD living in rural locations, and improving the quality of care delivered to patients with IBD. He has been funded by the NIH, AHRQ, the Crohn’s and Colitis Foundation, and the Leona M. and Harry B. Helmsley Charitable Trust for this work. Dr. Siegel is the founder of the BRIDGe group, an international research collaborative of IBD investigators. Dr. Siegel was inducted into the International Organization for the Study of IBD (IOIBD) in 2013 and he received the Sherman Prize in 2023. He lives in Hanover, New Hampshire with his wife and three boys.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

David T. Rubin is the Joseph B. Kirsner Professor of Medicine, Professor of Pathology, Chief of the Section of Gastroenterology, Hepatology & Nutrition and Director of the Inflammatory Bowel Disease Center at the University of Chicago Medicine. He earned a medical degree with honors at The University of Chicago Pritzker School of Medicine where he also completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics. He is associate faculty member at the MacLean Center for Clinical Medical Ethics, associate investigator at the University of Chicago Comprehensive Cancer Center and a member of the University of Chicago Committee on Clinical Pharmacology and Pharmacogenomics. He is the immediate past Chair of the National Scientific Advisory Committee of the Crohn’s & Colitis Foundation and Deputy Chair of the International Organization for the Study of IBD.
Dr. Rubin’s research is focused on disease modification in IBD including clinical trial designs, novel measures of inflammation and prevention of adverse outcomes, and quality of life in IBD. In 2023, he received both the UChicago Michael Reese Lectureship Award (for outstanding faculty who have developed novel teaching and clinical research that advances healthcare) and the distinguished UChicago Arthur H. Rubenstein Mentorship in Academic Medicine Award. Dr. Rubin is currently a senior editor of the 12 edition of Sleisenger and Fordtran’s Gastrointestinal and Liver Disease, and an author on >600 articles on management of IBD, including the 2019 and 2025 ACG Guidelines for ulcerative colitis.

Edward L. Barnes, MD, MPH is an Associate Professor of Medicine in the Division of Gastroenterology & Hepatology and Co-Director of the Multidisciplinary Inflammatory Bowel Diseases Center at the University of North Carolina of Chapel Hill. Dr. Barnes received his undergraduate and medical degrees from the University of South Carolina. He completed his internship, residency, and chief residency in internal medicine at the University of North Carolina. He completed his gastroenterology fellowship at Brigham and Women’s Hospital in Boston, Massachusetts. During his gastroenterology fellowship, Dr. Barnes received a Master of Public Health from the Harvard TH Chan School of Public Health. Following his gastroenterology fellowship, Dr. Barnes completed a one year advanced fellowship in inflammatory bowel disease at the University of North Carolina.

Dr. Barnes has a research interest in the epidemiology and clinical outcomes of patients with inflammatory bowel disease. He has a particular interest in improving our understanding of inflammatory conditions of the pouch after restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA). He has received funding from the National Institutes of Health, Crohn’s & Colitis Foundation, American College of Gastroenterology, and American Gastroenterological Association to study clinical outcomes of patients with pouchitis and other pouch-related conditions and to investigate predictors of a complicated disease course after IPAA. Dr. Barnes is the 2021 Sherman Emerging Leader Prize recipient.

Raymond K. Cross, MD, MS, AGAF, FACG completed undergraduate training at Washington and Jefferson College and attended medical school at the University of Pittsburgh. He completed internal medicine residency and gastroenterology and Hepatology fellowship training at the University of Maryland Medical Center and Baltimore Veterans Affairs. Prior to fellowship, he was a Chief Medical Resident. He obtained a Master’s Degree in Clinical Research at the University of Maryland, Baltimore. He joined the faculty at the University of Maryland and served as Director of the Inflammatory Bowel Disease Program from 2004 to 2024. In July 2024, he joined the faculty at the Melissa L. Posner Institute for Digestive Health & Liver Disease at Mercy Medical Center where he is Director of the Center for Inflammatory Bowel and Colorectal Diseases.
He has published over 200 peer reviewed manuscripts, review articles, and book chapters and has obtained research funding from the Agency for Healthcare Research and Quality, the Crohn’s and Colitis Foundation, and the American College of Gastroenterology. He is past Chair of the Patient Education and Clinical Research Committees and Clinical Research Alliance for the Foundation. He is the Co-Chair of the Regional Advances in Inflammatory Bowel Disease Course, Scientific Co-Director of the CorEvitas Registry, and past Course Director for the American College of Gastroenterology’s Eastern Regional Course. He is Governor for Maryland for the American College of Gastroenterology, a member of the American College of Gastroenterology’s Research Committee, and Senior Associate Editor of the American Journal of Gastroenterology.

Dr. Anthony de Buck, MD, MSc, is a colorectal surgeon and internationally recognized expert in inflammatory bowel disease (IBD). He currently practices at the Cleveland Clinic in Ohio, where he serves as colorectal surgeon and Lead of the IBD Section within the Department of Colorectal Surgery. He also holds an academic appointment as Visiting Associate Professor of Surgery at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.
Dr. de Buck recently transitioned from Mount Sinai Hospital in Toronto, where he was a colorectal surgeon and Associate Professor of Surgery at the University of Toronto.
He earned his medical degree at the University of Leuven, where he also completed his surgical and colorectal training. In 2013, he completed a colorectal fellowship at the University of Toronto, refining his expertise under the mentorship of leading experts in the field. He also holds a Master’s Degree in Clinical Epidemiology from the University of Toronto, equipping him with advanced research methodology skills.
Dr. de Buck’s research focuses on clinical outcomes in IBD, particularly functional results and quality of life. He has led and contributed to several multi-institutional studies and randomized controlled trials, supported by peer-reviewed funding. His work continues to shape surgical care for patients with IBD.
An engaged educator and academic leader, Dr. de Buck remains actively involved in teaching and mentorship. He is widely recognized for his contributions to patient-centered innovation in colorectal surgery.

Dr. Kaplan is a Professor in the Cumming School of Medicine at the University of Calgary. Dr. Kaplan is a gastroenterologist who is internationally renowned for studying the global epidemiology of inflammatory bowel disease (IBD). As the corresponding author, he has published in prestigious journals such as Nature, The Lancet and JAMA. He is an Associate Editor of Gastroenterology and an Academic Editor of PLOS Med. Between 2020 and 2025 Clarivate, Web of Science named Dr. Kaplan a Highly Cited Researcher in recognition of being in the top one percent of cited researchers. Dr. Kaplan is a member of the International Organization for the study of IBD (IOIBD). Dr. Kaplan received Canadian Association of Gastroenterology’s Research Leader Award and was inducted into the Canadian Academy of Health Sciences.

Dr Nuru Noor is a Clinical Lecturer in Gastroenterology based at the University of Cambridge in the UK. He also works as a Postdoctoral Research Associate at the Medical Research Council Clinical Trials Unit - the largest academic clinical trials unit in Europe. He has a particular interest in novel clinical trial designs, having completed his PhD on this topic. He is keen to bring novel methodological approaches to the field of Gastroenterology, and in particular to IBD - which is his main area of clinical interest and expertise.

Dr. Kara De Felice serves as an Associate Professor of Clinical Medicine and the Director of Inflammatory Bowel Diseases at the University of Cincinnati. Leading a multidisciplinary IBD team, her mission is to deliver exceptional patient care and improve long-term outcomes through clinical excellence, participation in clinical trials, and the training of the next generation of gastroenterologists. A dedicated educator, she is a frequent speaker at regional and national conferences with a specialized focus on women in GI and Advanced Practice Provider (APP) education. Outside of the clinic, she enjoys traveling, playing tennis, and hosting dinner and cocktail parties.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.

Bincy P. Abraham, M.D., M.S., AGAF, FACG, FASGE, FCCF is the Distinguished Professor and Director of the Fondren Inflammatory Bowel Disease Program at the Underwood Digestive Diseases Center of Houston Methodist Hospital. She is also the Program Director for the Gastroenterology Fellowship and Associate Program Director of the Advanced IBD Fellowship at Houston Methodist Hospital. She earned her medical degree from University of Texas Medical Branch, Galveston, TX, where she continued with residency training in internal medicine and fellowship in gastroenterology. During fellowship, she received specialized training in inflammatory bowel disease and earned her degree in Masters of Clinical Investigation. She also completed a National Visiting Fellow Inflammatory Bowel Disease Rotation program through the Crohn’s and Colitis Foundation in Cedars Sinai Hospital in Los Angeles. She has chaired the Southern Regional chapter of the CCFA Medical Advisory Committee, served as president of the Texas Gulf Coast Gastroenterology Society, is involved in national committees for and is a Fellow of the American College of Gastroenterology, American Gastroenterology Association, American Society of Gastrointestinal Endoscopy, and Crohn's and Colitis Foundation. She is trained in and passionate about intestinal ultrasound in IBD patient care.

Jessica Caron, MS is a passionate healthcare professional and patient advocate in the Inflammatory Bowel Disease (IBD) community. As a nationally-recognized speaker on patient advocacy, Jessica shares her experience as a patient living with Crohn’s disease, advocating for a co-facilitated approach to advancing medical care. She blogs and supports patients across the globe through her website, Chronically-Jess.com. Jessica has been a Patient Leader with the Crohn’s and Colitis Foundation’s IBDQorus program, a past member of the Patient Engagement Committee with the Academy on Communication in Healthcare, and is an active advocate through social media. She has a Psychology degree from the University of Maine, a Master of Education in Human Relations from Plymouth State University, and a Master's in Health Care Delivery Science (MHCDS) from Dartmouth College. Jessica currently lives in New Hampshire with her husband and two young sons and works in strategic patient engagement with Snow Companies.

Dr. Sara Horst MD, MPH, FACG, AGAF is a Professor in the division of Gastroenterology, Hepatology, & Nutrition at Vanderbilt University Medical Center. Dr. Horst completed her medical school and residency training at The Ohio State University and then went to Vanderbilt University Medical Center for Gastroenterology Fellowship and to obtain her Masters of Public Health. She joined the faculty at Vanderbilt University Medical Center in 2011. She is involved in clinical care of complex IBD care, complex amyloid care, clinical research, and teaching and mentoring medical students and housestaff. She is the medical director for VUMC Specialty Pharmacy, VUMC Telehealth director, and VUMC Associate Vice Chair of Clinical Affairs for Dept of Medicine. Her research interests involve enhancing EHR efficiencies in the care of IBD, telehealth in IBD, and medication adherence in IBD. She has extensively published in peer reviewed journals. She is also involved in clinical care improvement as an EPIC Physician Builder and is on the National EPIC GI Steering Board. She is an associate editor for American Journal of Gastroenterology.

David Schwartzberg, MD is a double-board certified colorectal surgeon who specializes in the treatment of inflammatory bowel disease, including redo/corrective pelvic pouch surgery in the Center for Advanced IBD at Northwell Health. He completed his general surgery training at NYU, a colorectal fellowship at Cleveland Clinic and an complex IBD & J-pouch surgery fellowship at NYU's IBD Center.
He is currently at Lenox Hill Hospital in New York City and serves as the director of reoperative surgery. & the intestinal fistula center.

Millie D. Long MD, MPH earned her doctor of medicine degree at the University of Virginia. She completed a residency and chief residency in internal medicine at the University of Alabama at Birmingham. She then completed a gastroenterology fellowship at University of North Carolina. She also completed a fellowship in preventive medicine and a masters of public health in epidemiology at the Gillings School of Public Health. She is board certified in internal medicine, preventive medicine, and gastroenterology. She is currently Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina, as well as Chief of the Division.

Dr. Long’s clinical practice is at the UNC Multidisciplinary Inflammatory Bowel Diseases (IBD) center. Her research interests include prevention of complications of IBD, women’s health and clinical epidemiology. Dr. Long has contributed over 200 peer-reviewed publications, book chapters, and review articles to the literature. She co-authored the 2025 ACG ulcerative colitis guidelines. She serves Co-Editor in Chief of the American Journal of Gastroenterology.

Dr. Long is a fellow of the American College of Gastroenterology where she is a member of the Board of Trustees. She is also a fellow of the American Gastroenterological Association and a member of the Crohn’s and Colitis Foundation. Recipient of the 2024 Sherman Prize for Excellence in Crohn’s and Colitis. She is a member of the International Organization for the Study of IBD.